Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Operating Margin: 2022-2025

Historic Operating Margin for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to -163.66%.

  • ARS Pharmaceuticals' Operating Margin rose 88798.00% to -163.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -63.59%, marking a year-over-year increase of 226536.00%. This contributed to the annual value of -3.46% for FY2024, which is 22506321.00% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Operating Margin stood at -163.66% for Q3 2025, which was up 45.98% from -302.95% recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Operating Margin ranged from a high of 54.51% in Q4 2024 and a low of -206,030.00% during Q2 2023.
  • For the 3-year period, ARS Pharmaceuticals' Operating Margin averaged around -38,074.13%, with its median value being -758.97% (2025).
  • In the last 5 years, ARS Pharmaceuticals' Operating Margin plummeted by 20,466,276bps in 2023 and then soared by 20,296,200bps in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Operating Margin (Quarterly) stood at -3,507.94% in 2022, then tumbled by 20,466,276bps to -206,030.00% in 2023, then skyrocketed by 20,296,200bps to 54.51% in 2024, then soared by 88,798bps to -163.66% in 2025.
  • Its last three reported values are -163.66% in Q3 2025, -302.95% for Q2 2025, and -466.29% during Q1 2025.